Manufacturer record
Kerala State Drugs and Pharmaceuticals Ltd: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
19 batches manufactured by Kerala State Drugs and Pharmaceuticals Ltd (Kerala) were declared Not of Standard Quality between October 2024 and August 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: TM5145, Telmisartan Tablets IP 40 mg (exp Aug 2027). DTL, Thrissur (state lab) found it not of standard quality: The sample does not conform to IP standards with respect to Description. Listed in the August 2026 alert.
Records by type
19 records linked to Kerala State Drugs and Pharmaceuticals Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Telmisartan Tablets IP 40 mg | Batch TM5145Mfg Sep 2025 · Exp Aug 2027 | The sample does not conform to IP standards with respect to Description.Description | DTL, ThrissurState lab | Aug 2026 |
| Telmisartan Tablets IP 40 mg | Batch TM 5139Mfg Sep 2025 · Exp Aug 2027 | The sample does not conform to IP standards with respect to Description.Description | DTL, ThrissurState lab | Aug 2026 |
| Diclofenac Sodium Tablets IP 50 mg | Batch DG5027Mfg Feb 2025 · Exp Jan 2027 | Sample does not conform to IP standards with respect to the test Dissolution and also shows category B defect of tablets (Capping) as described under DCC Guidelines on NSQ DrugsDissolution | RDTL, EKMState lab | Aug 2026 |
| Telmisartan Tablets IP 40 mg | Batch TM5143Mfg Sep 2025 · Exp Aug 2027 | It fails the Descriptive part for tablets as per IP, as specified in the laboratory protocol. As per IP, tablets should have sufficient hardness to withstand handling without crumbling or breaking. These tablets are soft and in powdered condition and cannot be removed from the strips in intact formOther | DTL, TVPMState lab | Jun 2026 |
| Diclofenac Sodium Tabelts IP 50 mg | Batch DG5034Mfg Mar 2025 · Exp Feb 2027 | The sample does not conform to IP standards. If fails the Descriptive part as per IP,as specified in the Laboratory Protocol.Other | DTL TVPMState lab | Jun 2026 |
| Telmisartan Tablets IP 40 mg | Batch TM 5144Mfg Sep 2025 · Exp Aug 2027 | DescriptionDescription | DTL ThrissurState lab | May 2026 |
| Telmisartan Tablets IP 40 mg | Batch TM5142Mfg Sep 2025 · Exp Aug 2027 | DescriptionDescription | DTL ThiruvananthapuramState lab | May 2026 |
| Diclofenac Sodium Tablets IP 50mg | Batch DG 5031Mfg Feb 2025 · Exp Jan 2027 | Dissolution.Dissolution | DTL ThiruvananthapuramState lab | May 2026 |
| Folic Acid Tablets IP 5mg | Batch F65092Mfg Aug 2025 · Exp Jul 2028 | Sample fails the test Dissolution as per IPDissolution | DTL, ThiruvananthapuramState lab | Mar 2026 |
| Diclofenac Sodium Tablets IP 50mg | Batch DG5028Mfg Feb 2025 · Exp Jan 2027 | Dissolution as per IPDissolution | DTL, ThrissurState lab | Mar 2026 |
| Doxycycline Hyclate Tablets USP-100MG | Batch DX 5042Mfg Jan 2025 · Exp Dec 2028 | Sample fails the test Dissolution as per USP as specified in the Laboratory ProtocolDissolution | DTL ThiruvananthapuramState lab | Feb 2026 |
| Glimepiride Tablets IP 2mg | Batch GL 4142Mfg Nov 2024 · Exp Oct 2026 | It fails the test "Dissolution". as per IP.Dissolution | DTL ThrissurState lab | Nov 2025 |
| Glimepiride Tab IP 1 mg | Batch GP4053Mfg Mar 2024 · Exp Feb 2026 | It fails the Descriptive part for tablets as specified in the Laboratory Protocol as per IPOther | Drugs Testing Laboratory ThiruvananthapuramState lab | Mar 2025 |
| Glimepiride Tab IP | Batch GP4039Mfg Mar 2024 · Exp Aug 2026 | It fails the test ?Dissolution? Specified in the laboratory protocol as per IPDissolution | Drugs Testing Laboratory ThiruvananthapuramState lab | Mar 2025 |
| Cetirizine Syrup IP | Batch CE3010Mfg Sep 2023 · Exp Aug 2025 | It fails the test ?Assay? as per IPAssay | DTL ThiruvananthapuramState lab | Jan 2025 |
| Cetirizine Syrup IP | Batch CE 3008Mfg Sep 2023 · Exp Aug 2025 | It fails the test Assay and content of packaged dosage forms specified in the laboratory protocol as per IPAssay | DTL ThiruvananthapuramState lab | Jan 2025 |
| Cetirizine Syrup IP | Batch CE4019Mfg May 2024 · Exp Apr 2026 | It fails the tests Microbial contamination in non- sterile products as per IPMicrobial limits | DTL ThiruvananthapuramState lab | Jan 2025 |
| Chlorpromazine Tablets IP 50 mg | Batch S73010Mfg Mar 2023 · Exp Feb 2025 | The sample fails in the ?Descriptive Part? for Tablets as per IPOther | DTL ThiruvananthapuramState lab | Nov 2024 |
| Theophylline & Etophylline Tablets | Batch TE4029Mfg Apr 2024 · Exp Mar 2027 | It fails the test ?Disintegration? Specified in the Laboratory Protocol as per IPDisintegration | DTL ThiruvananthapuramState lab | Oct 2024 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.